Premium
Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
Author(s) -
Brefel C.,
Thalamas C.,
Rayet S.,
LopezGil A.,
Fitzpatrick K.,
Bullman S.,
Citerone D. R.,
Taylor A. C.,
Montastruc J. L.,
Rascol O.
Publication year - 1998
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1998.t01-1-00704.x
Subject(s) - ropinirole , pharmacokinetics , cmax , regimen , pharmacology , crossover study , agonist , levodopa , parkinson's disease , medicine , dopamine agonist , endocrinology , receptor , disease , placebo , alternative medicine , pathology
Aims Ropinirole is a specific non‐ergoline dopamine D 2 ‐receptor agonist with antiparkinsonian properties.The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co‐administered with food.Methods This was an open, randomized, two sessions cross over study in 12 patients with Parkinson’s disease, comparing the steady‐state pharmacokinetic profiles of ropinirole on two different study days: ‘fasted’ and ‘fed’.Results The mean C max was lower in the ‘fed’ regimen than in the ‘fasted’ one (−25%, P =0.002). The median t max was observed 2.6 h later in the ‘fed’ regimen than in the ‘fasted’ regimen ( P <0.05). There was a slight but significant decrease in AUC(0,8 h) in the ‘fed’ regimen ( P =0.03).Conclusions Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.